Unknown

Dataset Information

0

Lymphoproliferative disorder during temozolomide therapy; a representative case of a formidable complication and management challenges.


ABSTRACT:

Background

Lymphoproliferative disorder represents a heterogeneous clinicopathological spectrum characterized by uncontrolled proliferation of lymphocytes. Immunodeficiency is a major trigger of its development. While induction of immunodeficiency is a well-known adverse effect of temozolomide therapy, development of lymphoproliferative disorder following temozolomide therapy has not previously been described.

Case presentation

A patient with brainstem glioma developed constitutional symptoms, pancytopenia, splenomegaly and generalized lymphadenopathy during the 2nd cycle of maintenance therapy following induction therapy with temozolomide. Epstein-Barr virus-infected lymphocytes were observed histopathologically and "other iatrogenic immunodeficiency-associated lymphoproliferative disorder" (OIIA-LPD) was diagnosed. Although discontinuation of temozolomide led to rapid remission, relapse was observed 4 months later. CHOP chemotherapy was induced, resulting in secondary remission. Vigilant follow-up for another 14 months showed radiologically stable brainstem glioma and no further recurrence of OIIA-LPD.

Conclusions

This is the first report documenting OIIA-LPD during temozolomide administration. Timely diagnosis of the disease and discontinuation of the causative agent were considered to be the management of choice. Close monitoring for relapse should be continued. Finding a balance between glioma management and controlling the remission of OIIA-LPD remains to be clarified.

SUBMITTER: Sato D 

PROVIDER: S-EPMC10251676 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Lymphoproliferative disorder during temozolomide therapy; a representative case of a formidable complication and management challenges.

Sato Daisuke D   Takami Hirokazu H   Takayanagi Shunsaku S   Taoka Kazuki K   Tanaka Mariko M   Matsuura Reiko R   Tanaka Shota S   Saito Nobuhito N  

BMC neurology 20230609 1


<h4>Background</h4>Lymphoproliferative disorder represents a heterogeneous clinicopathological spectrum characterized by uncontrolled proliferation of lymphocytes. Immunodeficiency is a major trigger of its development. While induction of immunodeficiency is a well-known adverse effect of temozolomide therapy, development of lymphoproliferative disorder following temozolomide therapy has not previously been described.<h4>Case presentation</h4>A patient with brainstem glioma developed constitutio  ...[more]

Similar Datasets

| S-EPMC5537377 | biostudies-other
| S-EPMC6174745 | biostudies-literature
| S-EPMC3079420 | biostudies-other
| S-EPMC8589110 | biostudies-literature
| S-EPMC11828662 | biostudies-literature
| S-EPMC7020916 | biostudies-literature
| S-EPMC8339712 | biostudies-literature
| S-EPMC5878077 | biostudies-literature
| S-EPMC5110512 | biostudies-other
| S-EPMC7649444 | biostudies-literature